Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSULET CORPPODD · Entity 3516 | Director · President and CEO | August 21, 2026 | August 24, 2026 |
| JOHNSON & JOHNSONJNJ · Entity 2722 | EVP, WW Chair, MedTech | August 23, 2023 | August 25, 2023 |
| PROCTER & GAMBLE CoPG · Entity 2814 | Director | October 13, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSULET CORP
Report date August 21, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,731 |
Reported balance
After 2026-08-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-21 · Purchase · Acquired 1,100 · Balance 23,731 F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $147.42 to $147.62. The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. F2: Includes 80 shares acquired under the Insulet Corporation Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 filing. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 4 |
Reported balance
Holding disclosure · report date 2026-08-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $147.42 to $147.62. The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Includes 80 shares acquired under the Insulet Corporation Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 filing.
JOHNSON & JOHNSON
Report date August 23, 2023 · Filed August 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,037.9545 |
Reported balance
After 2023-08-23 transaction · row 1
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 2,787 · Balance 52,037.9545 F1: The Compensation & Benefits Committee of the Board of Directors of Johnson & Johnson approved the disposition of these shares of Johnson & Johnson common stock. F2: On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer. |
| Common StockSEC Table I · non-derivative | IndirectBy 401k | 2,806 |
Reported balance
Holding disclosure · report date 2023-08-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,806 F3: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023). |
| Common StockSEC Table I · non-derivative | IndirectBy ESOP | 300 |
Reported balance
Holding disclosure · report date 2023-08-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 300 F4: Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023). |
Filing footnotes · ownership attribution and instrument terms
F1: The Compensation & Benefits Committee of the Board of Directors of Johnson & Johnson approved the disposition of these shares of Johnson & Johnson common stock.
F2: On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer.
F3: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023).
F4: Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023).
PROCTER & GAMBLE Co
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,666.0049 |
Reported balance
After 2026-10-13 transaction · row 1
1 source rowRow 1 · 2026-10-13 · Grant · Acquired 1,438 · Balance 7,666.0049 F1: Common Stock awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2026 Filed Oct 14, 2026 19:56 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-26-000223 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,666.0049 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 18:34 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 207 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-26-000165 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,228.0049 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 11:08 UTC | INSULET CORP PODD · Entity 3516 | PurchaseCommon Stock | 1,100 | $147.47 | $162,217.00 |
DisclosureSEC source: 0001145197-26-000172 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,731 F1 · price: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $147.42 to $147.62. The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 80 shares acquired under the Insulet Corporation Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 filing. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 18:26 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 202 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-26-000076 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,986.2484 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:21 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 1,411 | $148.84 | $210,013.24 |
DisclosureSEC source: 0001145197-26-000105 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,551 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 18:06 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-26-000032 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,751.065 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:03 UTC | INSULET CORP PODD · Entity 3516 | GrantEmployee Stock Option (Right to Buy) · Derivative | 26,143 | $0.00 Strike: $245.25 | $0.00 |
DisclosureSEC source: 0001145197-26-000058 · form4.xml · derivative · entry 3 McEvoy Ashley · CIK 0001745936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,143 Underlying: Common Stock · 26,143 shares Expires 2036-02-24 F2 · derivative.exercise_date: Annual Non-Qualified Stock Option ("Option") Award. The Options become exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:03 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 10,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-26-000058 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,962 F1 · shares: Annual Restricted Stock Unit ("RSU") award. RSUs vest in substantially equal installments on each of the first, second and third anniversaries of the grant date and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 13:14 UTC | INSULET CORP PODD · Entity 3516 | PurchaseCommon Stock | 4,300 | $239.35 | $1,029,205.00 |
DisclosureSEC source: 0001145197-26-000031 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,916 F1 · price: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $238.55 to $241.56. Specifically: 2,794 shares were purchased in the range of $238.55 to $238.78, at a weighted average share price of $238.63; 511 shares were purchased in the range of $239.64 to $240.61, at a weighted average share price of $240.06; F2 · price: Footnote continued: 995 shares were purchased in the range of $240.66 to $241.56, at a weighted average share price of $241.01. The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. F3 · balance_after: Includes 76 shares acquired under the Insulet Corporation Stock Purchase Plan since the date of the Reporting Person's last Section 16 filing. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 21:19 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 215 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-25-000283 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,562.7456 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 19:18 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-25-000228 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,318.0241 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 17:08 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 189 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-25-000150 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,843.0241 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 18:50 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 185 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017273 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,636.1013 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:24 UTC | INSULET CORP PODD · Entity 3516 | GrantEmployee Stock Option (Right to Buy) · Derivative | 24,150 | $314.46 Strike: $314.46 | $7,594,209.00 |
DisclosureSEC source: 0001127602-25-014457 · form4.xml · derivative · entry 3 McEvoy Ashley · CIK 0001745936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,150 Underlying: Common Stock · 24,150 shares Expires 2035-05-13 F2 · derivative.exercise_date: The Options become exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:24 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 9,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014457 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,540 F1 · shares: Restricted Stock Unit ("RSU") award. RSUs vest in equal installments on each of the first, second and third anniversaries of the grant date and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 17:34 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 145 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009205 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,433.9488 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 19:57 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-029124 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,273.0268 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| October 08, 2024 Filed Oct 9, 2024 16:07 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025357 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,082.6443 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 18:21 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 169 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023769 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,773.6443 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 21:03 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 180 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018465 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,597.0927 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 16:01 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009941 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,409.4819 F1 · price: Common Stock awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 20:18 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029613 · form4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,247 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:07 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Disposition to issuerCommon Stock | 2,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-008459 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,037.9545 F1 · kind: The Compensation & Benefits Committee of the Board of Directors of Johnson & Johnson approved the disposition of these shares of Johnson & Johnson common stock. F2 · price: On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:24 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 3,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002062 · doc4.xml · derivative · entry 6 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,704 Underlying: Common Stock · 3,704 shares Expires not disclosed F5 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to acquire one share of Common Stock. F6 · derivative.exercise_date: The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:24 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 61,295 | $0.00 Strike: $162.75 | $0.00 |
DisclosureSEC source: 0001225208-23-002062 · doc4.xml · derivative · entry 5 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,295 Underlying: Common Stock · 61,295 shares Expires 2033-02-13 F4 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:24 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 7,158 | $162.01 | $1,159,667.58 |
DisclosureSEC source: 0001225208-23-002062 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,824.9545 Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:24 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantCommon Stock | 17,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002062 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,982.9545 F1 · shares: Represents Common Stock received upon the satisfaction of performance and time-based criteria for Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 10, 2020. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:36 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 2,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-001906 · doc4.xml · derivative · entry 5 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Share Units awarded under Long-Term Incentive Plan on February 10, 2020 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. F1 · derivative.exercise_date: Restricted Share Units awarded under Long-Term Incentive Plan on February 10, 2020 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. F1 · derivative.expiration_date: Restricted Share Units awarded under Long-Term Incentive Plan on February 10, 2020 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:36 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 823 | $162.08 | $133,391.84 |
DisclosureSEC source: 0001225208-23-001906 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,988.9545 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:36 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 2,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-001906 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,811.9545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Share Units awarded under Long-Term Incentive Plan on February 10, 2020 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:32 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 73,323 | $0.00 Strike: $72.54 | $0.00 |
DisclosureSEC source: 0001225208-22-012182 · doc4.xml · derivative · entry 6 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,323 shares Expires 2023-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:32 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 71,923 | $175.46 | $12,619,271.54 |
DisclosureSEC source: 0001225208-22-012182 · doc4.xml · nonDerivative · entry 3 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,812.9545 F2 · price: This transaction was executed in multiple trades at prices ranging from $175.040 to $176.010. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:32 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 1,400 | $176.09 | $246,529.22 |
DisclosureSEC source: 0001225208-22-012182 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,735.9545 F1 · price: This transaction was executed in multiple trades at prices ranging from $176.050 to $176.115. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 21:32 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 73,323 | $72.54 | $5,318,850.42 |
DisclosureSEC source: 0001225208-22-012182 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, MedTech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,135.9545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 11:01 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 15,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002373 · doc4.xml · derivative · entry 7 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,506 Underlying: Common Stock · 15,806 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited. F7 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 11:01 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 6,242 | $165.89 | $1,035,485.38 |
DisclosureSEC source: 0001225208-22-002373 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,812.9545 F2 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 11:01 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 15,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002373 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,054.9545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 01:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 2,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002214 · doc4.xml · derivative · entry 5 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,885 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 01:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 792 | $168.85 | $133,729.20 |
DisclosureSEC source: 0001225208-22-002214 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,248.9545 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 01:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 2,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002214 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,040.9545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 11:01 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 3,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002373 · doc4.xml · derivative · entry 6 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,347 Underlying: Common Stock · 3,347 shares Expires not disclosed F6 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F6 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 11:01 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 66,110 | $165.89 | $10,966,987.90 |
DisclosureSEC source: 0001225208-22-002373 · doc4.xml · derivative · entry 5 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,110 Underlying: Common Stock · 66,110 shares Expires 2032-02-14 F5 · security: Awarded under Issuer's Long-Term Incentive Plan. F5 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · derivative · entry 8 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,102 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F2 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 11,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · derivative · entry 7 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,034 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 4,090 | $165.55 | $677,099.50 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · nonDerivative · entry 4 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,155.9545 F4 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 588 | $165.55 | $97,343.40 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · nonDerivative · entry 3 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,245.9545 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,833.9545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 11,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,731.9545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:47 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 3,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002097 · doc4.xml · derivative · entry 3 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,136 Underlying: Common Stock · 3,136 shares Expires not disclosed F3 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F3 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:47 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPerformance Share Units · Derivative | 11,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002097 · doc4.xml · derivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,034 Underlying: Common Stock · 11,034 shares Expires not disclosed F2 · derivative.exercise_price: On February 8, 2021, the Issuer's Compensation & Benefits Committe certified the performance factor applicable to Performance Share Units awarded to the reporting person on February 12, 2018 under the Issuer's Long-Term Incentive Plan. These Performance Share Units represent a contingent right to an equal number of shares of Common Stock or the cash value thereof, subject to the reporting person's continued service to the Issuer through the third anniversary of the initial award date. F2 · derivative.expiration_date: On February 8, 2021, the Issuer's Compensation & Benefits Committe certified the performance factor applicable to Performance Share Units awarded to the reporting person on February 12, 2018 under the Issuer's Long-Term Incentive Plan. These Performance Share Units represent a contingent right to an equal number of shares of Common Stock or the cash value thereof, subject to the reporting person's continued service to the Issuer through the third anniversary of the initial award date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.